From the press release, it sounds like (A) they are simply re-financing an existing bridge loan (B) presumably, with a higher rate of interest, at a lower rate of interest with the note issuance. The former is fact; the latter speculation.
KMI was/is a C corp, so your analysis is based upon inaccurate facts.
However, your idea is a sound one as applied to KMP. Indeed, KMP was/is the Alerian MLP Index's No. 1 holding at 10.7% and the four largest Alerian licensees held $2.2 Billion worth of KMP as of 8-15-14. Once KMP ceases to be an MLP, those funds will have to be re-invested by index funds elsewhere.
The other thing is that LINE was, at one point, booted out of one of the Alerian indexes because the share price was too low. That's no longer the case. Thus, there's a likelihood LINE will be re-added at some point.
Got out yesterday at $42.41. Had a bad feeling about declining soda sales generally.
$37 to $37.50 is the probable buy back in range.
Selling domestic oil companies, LINE or otherwise, in the face of global turmoil and rising oil prices makes no sense, yet that's exactly what happened to several of them, including LINE.
Fraud requires a false statement/misrepresentation of fact.
Opinion is protected by the First Amendment and, as Dirty Harry once said, are like @zzholes, everybody has one.
ETP, KMP, OXY, etc. are all down today too. With concerns over a potential explosion in Iraq over the weekend, there may be some short covering heading into the close.
Not only that, but LINE was featured prominently as one of his stock picks in his latest book. That book, Get Rich Carefully, was published AFTER the LINE accounting for derivatives issue was first raised. So, Cramer didn't seem to care about it then.
According to stockconsultant, TEVA broke through double resistance at $53.18. There's a 75% chance TEVA reaches an interim target of $56.52, which is a 6% increase, before resistance is reached again.
The name of the lead case was: Yanise Germain v. TEVA Pharmaceuticals USA, Inc., with the initial citation 14a0134p.06.
The United States Sixth Circuit Court of Appeals affirmed the dismissal of 67 of 68 lawsuits (except one against Eli Lilly), which arose from the Plaintiffs use of propoxlyene. All of the suits against TEVA were dismissed.